Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology Network by Cosgrove D, Tan R, Osterland AJ, Hernandez S, Ogale S, Mahrus S, Murphy J, Wilson T, Patton G, Loaiza-Bonilla A, Singal AG

Get full text

ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab by Stefanini B, Fulgenzi CAM, Scheiner B, Korolewicz J, Cheon J, Nishida N, Ang C, Marron TU, Wu YL, Saeed A, Wietharn B, Rimassa L, Pirozzi A, Cammarota A, Pressiani T, Pinter M, Balcar L, Huang YH, Mehan A, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Samson A, Galle PR, Kudo M, Manfredi GF, Celsa C, Awosika N, Cortellini A, Singal AG, Sharma R, Chon HJ, Tovoli F, Piscaglia F, Pinato DJ, D'Alessio A

Get full text